




## Coalition Innovation Santé: Cureety supported by Servier and Ipsen to accelerate the deployment of its solution ensuring the continuity of care for patients with cancer

June 15<sup>th</sup>, 2020, Dinan, Paris (France) – In the framework of the selection of its project by the Coalition Innovation Santé, Cureety announces it has obtained the institutional support of the Servier Group and Ipsen. This support will enable an acceleration in the deployment of the Cureety telemonitoring solution for patients with cancer\* and who, in this health crisis context, have an increased need for medical monitoring. The Coalition Innovation Santé program, which brings together public and private healthcare players, contributes to easing the congestion in the healthcare system and ensures patients with chronic diseases continue to receive care despite the health crisis.

The Cureety platform is a CE-marked medical software device (class I) which makes it possible to monitor remotely and optimize the management of complex chronic diseases, first and foremost cancer. As a result of configurable algorithms and personalized questionnaires, the Cureety application is able to accompany the patient and direct him/her towards the most appropriate treatment.



*"We welcome the alliance and the mobilization of healthcare players around the Coalition Innovation Santé program. We are convinced that we must unite to confront the health crisis, in particular to take concrete action for the most vulnerable patients and we are very happy to benefit from the support of the Servier Group and Ipsen for the deployment of our platform."*  
**François-Guirec Champoiseau, co-founder and President, Cureety.**



*"In the operations role of the Coalition Innovation Santé, we ensure that this collaboration between the players takes place quickly and efficiently. The support of key players such as Servier and Ipsen is a clear and strong message: manufacturers are showing their agility in adapting to the urgent context and providing help to patients."*  
**Didier Tranchier, co-founder Digital Pharma Lab**

\*except patients with lung or ovarian cancer, for whom Cureety has formed an exclusive partnership with another laboratory



*"For patients with cancer, the COVID-19 health Crisis is often synonymous with*

*difficulty in accessing healthcare. We are thrilled to be able to support Cureety in the deployment of their platform, which will allow patients to benefit more quickly from adapted treatment and healthcare personnel will be able to manage them better. This will be particularly important during this intense period when chronically ill patients are resuming consultations."*

**Olivier Nosjean, Scientific Director of Research, Servier**



*"We are very happy to partner with this platform which enables improvement in the treatment of*

*patients with chronic diseases, by allowing them to be monitored at home. The well-being of patients is the foundation of our mission at Ipsen."*

**Dominique Bery, Executive Vice-President in charge of strategy and digital transformation, Ipsen**

In particular, the Cureety platform makes it possible to:

- Reassure patients by ensuring a daily link with their healthcare institution: patients can share their different symptoms via the application and receive treatment recommendations.
- Streamline the medical time of carers who, thanks to the application, can prioritize the treatment of patients who need it most.
- Facilitate and safeguard the arrival of patients in the day hospital for the administration of their treatment.

The Cureety telemonitoring solution is already being used in 20 hospital centers nationally and counts over 3000 patient users.

As a result of Servier and Ipsen's support, the deployment of the Cureety platform into healthcare institutions will be accelerated, which will ensure the continuity of oncology treatment is facilitated within the COVID-19 context. The Servier Group will finance the deployment of Cureety in 5 healthcare centers and Ipsen will finance the deployment of Cureety in 2 centers.

This ambitious program may be deployed in less than 3 weeks, in line with the objectives of the Coalition Innovation Santé and within the current urgent health context. The commitment of the laboratories Servier and Ipsen is key in making it possible for Cureety to reach this objective.

## CONTACTS PRESSE

### CUREETY

Ophelie Philipot  
Cureety External Communication  
+33 (0)6 70 07 87 47  
+44 (0)7 522 376 860  
[Ophelie.Phillipot@comopi.tech](mailto:Ophelie.Phillipot@comopi.tech)

### Digital Pharma Lab (operator of the COALITION INNOVATION SANTE)

Tuyet Bunouf  
Marketing & Communication Manager  
+33 7 50 37 48 62  
+33 6 79 56 75 96  
[tbunouf@digitalpharmalab.com](mailto:tbunouf@digitalpharmalab.com)

### SERVIER

Sonia Marques  
+33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13  
[presse@servier.com](mailto:presse@servier.com)  
Jean-Clément Vergeau  
+33 (0)1 55 72 46 16 / +33 6 79 56 75 96  
[presse@servier.com](mailto:presse@servier.com)

### Ipsen

Véronique Delvolvé-Rosset  
Director of Public Affairs and Communication  
Ipsen France  
+33 7 63 45 11 97 / +33 1 58 33 67 96  
[veronique.delvolve@ipsen.com](mailto:veronique.delvolve@ipsen.com)

**About Cureety**

Cureety is a startup created in March 2018 by François-Guirec Champoiseau and Hugo Breitwiller. It is developing a CE-marked medical software device (class I) that makes it possible to monitor remotely and optimize the treatment of complex chronic diseases, first and foremost cancer. As a result of configurable algorithms and personalized questionnaires, the Cureety application is able to accompany patients and direct them to the most appropriate treatment. For healthcare teams, the platform allows them to streamline their resources and prioritize the treatment of the most vulnerable patients. Depending on the severity of the reported symptoms, the patient receives appropriate medical advice and, if needed, is encouraged to contact his or her healthcare team. Hospital services can therefore focus their efforts on the patients most in need and react more quickly, which should limit emergency hospitalizations. Cureety has a three-fold ambition. Cureety works to improve the quality of life of patients with complex diseases by accompanying them on a daily basis and by reacting in real time to their needs. Cureety innovates in the organization of hospital care by giving back time to medical teams without compromising the quality of patient care. Finally, Cureety also contributes to medical progress by collecting real-life data that will enable a better understanding of the management of patients with complex diseases. The solution is deployed in more than 20 healthcare institutions and ensures active monitoring of more than 3000 patients. Cureety is the winner of the 2019 class of AstraZeneca's REALIZE program, and incubated at Paris Biotech Santé at the Cochin Hospital in Paris. In 2020, Cureety is certified FrenchTechSeed. To find out more: [www.cureety.com](http://www.cureety.com)

**About the Coalition Innovation Santé**

The "Coalition Innovation Santé - Crise Sanitaire" was created at the initiative of France Biotech, France Digitale, MedTech in France and the biopharmaceutical company AstraZeneca, with the support of the AP-HP (Paris Hospitals), Bpifrance, EIT Health. Today the coalition's partners are Novartis, Sanofi, Servier, Ipsen, GSK, MSD, Roche, Pfizer France, Astellas, Medtronic, UCB, Grünenthal, Lilly, Amgen, Takeda, Chugai, Novo Nordisk, BMS, Mylan, Norgine, bioMérieux, Expanscience, La Diffusion Technique Française, Altran, Amazon Web Services, LEEM, G5 Santé, LIR, Urgo, La Cooper, Vivalto Santé, Alcimed, CapDecisif, l'AFSSI (Association Française des Sociétés de Services et d'Innovation), le SIDIV (Syndicat de l'Industrie et du Diagnostic In Vitro), SNITEM, PactePME, healthcare hubs of competition: Atlanpôle Biothérapies, Biovalley France, Clubster NSL, Eurobiomed, LyonBiopôle, Medicen Paris Région, Angels santé, HEC Santé, the French Multiple Sclerosis League, all mobilized to make solutions available as quickly as possible to patients with chronic diseases. The platform is implemented by Digital Pharma Lab, Europe's leading independent PharmaTech accelerator.

The coalition's appeal remains open to all players who could give their support to this mission and participate in this collective effort in the current context of the Covid-19 pandemic. For more information: <https://www.coalitioncovid.org>

**About Servier**

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

**About Ipsen**

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit [www.ipсен.com](http://www.ipсен.com)